Article information
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
A. Brewis.
Introduction.
[2.]
P. Barnes.
Autonomic pharmacology of the airways.
Pharmacology of the respiratory tract,
[3.]
A. Bugalho De Almeida.
Patogenía da asma brônquica.
Aspectos práticos da terapêutica da asma brônquica,
[4.]
H.L. Hahn.
Role of parasympathetic nervous system and of cholinergic mechanisms in bronchial hyperreactavity.
Bull Physiop. Respr, 22 (1986), pp. 122
[5.]
J.B. Richardson.
Nerve supply to the lungs.
Am Rev Respir. Dis., 119 (1979), pp. 785
[6.]
J.B. Richardson.
Recent progress in pulmonary innervati-on.
Am Rev. Respir. Dis, 128 (1983), pp. 565
[7.]
Bugalho De Almeida A., Emoniz D. Asma brônquica-in Pneumologia in Prática Clínica, 3a Ed., in press.
[8.]
A. Bugalho De Almeida.
Mecanismos broncoconstritores em patologia respiratória, Dissertação de doutoramento, (1982),
[9.]
D.B. Jacoby, A.D. Fryer.
Parasympathetic innervation of airways.
Pulmonary and critical care pharmacology and therapeutics,
[10.]
R.J. Pueringer, T.B. Casale.
Functional activity of lower-airway nerves.
Asthma and rhinitis,
[11.]
A.D. Fryer.
Muscarinic receptors.
Asthma and rhinitis,
[12.]
J.N. Baraninck.
Muscarinic receptors.
Pulmonary and critical care pharmacology and therapeutics,
[13.]
R.M. Englen, N. Watson.
Selective muscarinic receptors agonists and antagonists.
Pharmacology and Toxicology, 78 (1996), pp. 59
[14.]
R.K. Goyal.
Muscarinic receptors subtypes.
New Engl. J. Med, 15 (1989), pp. 1022
[15.]
P. Barnes.
Milestones in asthma treatment.
Eur. Respir. Rev, 1 (1991), pp. 247
[16.]
N.J. Gross.
Side effects and toxicity.
Pulmonary and critical care pharmacology and treatment,
[17.]
G.E. Pakes, R.N. Brogden, R.C. Heel, et al.
Ipratropium bromide: a review of its pharmacological propenies and therapeutic efficacy in asthma and chrome bronchitis.
Drugs, 20 (1980), pp. 237
[18.]
N.J. Gross, M.S. Skorodin.
Anticholinergic, anti-muscarinic bronchodilators.
Am Rev. Respir. Dis., 129 (1984), pp. 856
[19.]
K. Ensing, R.A. Zeeuw, G.D. Nossent.
al-Pharma-cokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration.
Eur. J. Clin. Pharmacol, 36 (1989), pp. 189
[20.]
Atsmon J..
Topics in clinical pharmacology: ipratropium bromide in COPD and asthma.
Am. J Med. Scien, 296 (1988), pp. 140
[21.]
Standards for the diagnosis and care of patients With Chronic Obstructive Pulmonary Disease.
Am. J. Respir. Crit. Care Med, 152 (1995), pp. 77
[22.]
P. Barnes.
Anticholinergics in COPD: theoretical implications.
Res. Clin. Forums, 13 (1991), pp. 33
[23.]
K.R. Chapman.
Clipieal implications of anticholinergic bronchodilator therapy in COPD.
Res. Clin. Forums, 13 (1991), pp. 43
[24.]
M.J. Barros, P.J. Rees.
Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airways obstrution.
Respir. Med., 84 (1990), pp. 371
[25.]
M.R. Partridge, K.B. Saunders.
Site of action of ipratropium bromide and cliniucal and physiological determinants of response in patients with asthma.
Thorax, 36 (1981), pp. 530
[26.]
P.J. Rees.
Effect of age on bronchodilator response.
Res. Clin. Forums, 13 (1991), pp. 15
[27.]
A.B. Miller, et al.
Ipratropium bromide: are patients treated with optimal therapy?.
Postgrad. Med. J, 66 (1990), pp. 1040
[28.]
Optimal assessment and management of chronic obstrutive pulmonary disease (COPD).
Eur. Respir. J., 8 (1995), pp. 1398
[29.]
K.R. Chapman.
Therapeutic algorithm for chronic obstructive pulmonary disease.
Am. J. Med, 91 (1991), pp. 17S
[30.]
K.R. Chapman.
Therapeutic approches to chronic obstructive pulmonary disease: an emerging consensus.
Am. J. Med, 100 (1996), pp. 5S
[31.]
M. Friedman.
Changing practices in COPD: a new pharmacologic treatment algorithm.
Chest, 107 (1995), pp. 1945
[32.]
A.S. Rebuck, K.R. Chapman, R. Abboud, et al.
Anticholinergic bronchodilators in acute and severe asthma.
Res. Clin. Forums, 13 (1991), pp. 69
Copyright © 1997. Sociedade Portuguesa de Pneumologia/SPP
Special content about COVID-19
- Hyperoxemia in invasively ventilated COVID–19 patients–Insights from the PRoVENT–COVID study
- Association between respiratory distress time and invasive mechanical ventilation in COVID-19 patients: A multicentre regional cohort study
- Assisted mobilisation in critical patients with COVID-19
- Two years of COVID-19: Trends in rehabilitation
Open access
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publish in
Pulmonology
Pulmonology
- Home
- All contents
- Publish your article
- About the journal
- Metrics
- Open access
Article options